Michael S. Rafii - Publications

2008-2016 Neuroscience University of California, San Diego, La Jolla, CA 
 2016- Neurology University of Southern California Keck School of Medicine 
Neurodegenerative Diseases

42 high-probability publications. We are testing a new system for linking publications to authors. You can help! If you notice any inaccuracies, please sign in and mark papers as correct or incorrect matches. If you identify any major omissions or other inaccuracies in the publication list, please let us know.

Year Citation  Score
2020 Craft S, Raman R, Chow TW, Rafii MS, Sun CK, Rissman RA, Donohue MC, Brewer JB, Jenkins C, Harless K, Gessert D, Aisen PS. Safety, Efficacy, and Feasibility of Intranasal Insulin for the Treatment of Mild Cognitive Impairment and Alzheimer Disease Dementia: A Randomized Clinical Trial. Jama Neurology. PMID 32568367 DOI: 10.1001/jamaneurol.2020.1840  0.84
2020 Donohue MC, Model F, Delmar P, Volye N, Liu-Seifert H, Rafii MS, Aisen PS. Initiation of symptomatic medication in Alzheimer's disease clinical trials: Hypothetical versus treatment policy approach. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. PMID 32270600 DOI: 10.1002/alz.12058  0.36
2019 van Dyck CH, Nygaard HB, Chen K, Donohue MC, Raman R, Rissman RA, Brewer JB, Koeppe RA, Chow TW, Rafii MS, Gessert D, Choi J, Turner RS, Kaye JA, Gale SA, et al. Effect of AZD0530 on Cerebral Metabolic Decline in Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 31329216 DOI: 10.1001/jamaneurol.2019.2050  0.84
2019 Iddi S, Li D, Aisen PS, Rafii MS, Thompson WK, Donohue MC. Predicting the course of Alzheimer's progression. Brain Informatics. 6: 6. PMID 31254120 DOI: 10.1186/s40708-019-0099-0  0.36
2019 Rafii MS, Donohue MC, Matthews DC, Muranevici G, Ness S, O'Bryant SE, Rissman RA. Plasma Neurofilament Light and Alzheimer's Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Journal of Alzheimer's Disease : Jad. PMID 31156181 DOI: 10.3233/JAD-190322  0.36
2018 Rafii MS, Aisen PS. Alzheimer's Disease Clinical Trials: Moving Toward Successful Prevention. Cns Drugs. PMID 30560544 DOI: 10.1007/s40263-018-0598-1  0.36
2018 Li D, Iddi S, Thompson WK, Rafii MS, Aisen PS, Donohue MC. Bayesian latent time joint mixed-effects model of progression in the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's & Dementia (Amsterdam, Netherlands). 10: 657-668. PMID 30456292 DOI: 10.1016/j.dadm.2018.07.008  0.36
2018 Rafii MS, Tuszynski MH, Thomas RG, Barba D, Brewer JB, Rissman RA, Siffert J, Aisen PS. Adeno-Associated Viral Vector (Serotype 2)-Nerve Growth Factor for Patients With Alzheimer Disease: A Randomized Clinical Trial. Jama Neurology. PMID 29582053 DOI: 10.1001/jamaneurol.2018.0233  0.84
2017 Rafii MS, Lukic AS, Andrews RD, Brewer J, Rissman RA, Strother SC, Wernick MN, Pennington C, Mobley WC, Ness S, Matthews DC. PET Imaging of Tau Pathology and Relationship to Amyloid, Longitudinal MRI, and Cognitive Change in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI). Journal of Alzheimer's Disease : Jad. 60: 439-450. PMID 28946567 DOI: 10.3233/JAD-170390  0.36
2017 Relkin NR, Thomas RG, Rissman RA, Brewer JB, Rafii MS, van Dyck CH, Jack CR, Sano M, Knopman DS, Raman R, Szabo P, Gelmont DM, Fritsch S, Aisen PS. A phase 3 trial of IV immunoglobulin for Alzheimer disease. Neurology. PMID 28381506 DOI: 10.1212/WNL.0000000000003904  0.84
2016 Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer's disease effects with imaging. Alzheimer's & Dementia (New York, N. Y.). 2: 69-81. PMID 28642933 DOI: 10.1016/j.trci.2016.02.004  0.36
2016 Rafii MS. Improving Memory and Cognition in Individuals with Down Syndrome. Cns Drugs. PMID 27272473 DOI: 10.1007/s40263-016-0353-4  0.84
2016 Matthews DC, Lukic AS, Andrews RD, Marendic B, Brewer J, Rissman RA, Mosconi L, Strother SC, Wernick MN, Mobley WC, Ness S, Schmidt ME, Rafii MS. Dissociation of Down syndrome and Alzheimer's disease effects with imaging Alzheimer's and Dementia: Translational Research and Clinical Interventions. 2: 69-81. DOI: 10.1016/j.trci.2016.02.004  0.84
2015 Rafii MS, Wishnek H, Brewer JB, Donohue MC, Ness S, Mobley WC, Aisen PS, Rissman RA. The down syndrome biomarker initiative (DSBI) pilot: proof of concept for deep phenotyping of Alzheimer's disease biomarkers in down syndrome. Frontiers in Behavioral Neuroscience. 9: 239. PMID 26441570 DOI: 10.3389/fnbeh.2015.00239  0.84
2015 Rafii MS, Aisen PS. Advances in Alzheimer's disease drug development. Bmc Medicine. 13: 62. PMID 25857341 DOI: 10.1186/s12916-015-0297-4  0.84
2014 Rafii MS. Pro: Are we ready to translate Alzheimer's disease modifying therapies to people with Down syndrome? Alzheimer's Research & Therapy. 6: 60. PMID 25478025 DOI: 10.1186/s13195-014-0060-7  0.84
2014 Rafii MS. Preclinical Alzheimer's disease therapeutics. Journal of Alzheimer's Disease : Jad. 42: S545-9. PMID 25079804 DOI: 10.3233/JAD-141482  0.84
2014 Rafii MS, Baumann TL, Bakay RA, Ostrove JM, Siffert J, Fleisher AS, Herzog CD, Barba D, Pay M, Salmon DP, Chu Y, Kordower JH, Bishop K, Keator D, Potkin S, et al. A phase1 study of stereotactic gene delivery of AAV2-NGF for Alzheimer's disease. Alzheimer's & Dementia : the Journal of the Alzheimer's Association. 10: 571-81. PMID 24411134 DOI: 10.1016/j.jalz.2013.09.004  0.84
2014 Rafii MS, Taylor CS, Kim HT, Desikan RS, Fleisher AS, Katibian D, Brewer JB, Dale AM, Aisen PS. Neuropsychiatric symptoms and regional neocortical atrophy in mild cognitive impairment and Alzheimer's disease. American Journal of Alzheimer's Disease and Other Dementias. 29: 159-65. PMID 24164929 DOI: 10.1177/1533317513507373  0.84
2013 Rafii MS. Update on Alzheimer's disease therapeutics. Reviews On Recent Clinical Trials. 8: 110-8. PMID 23859061 DOI: 10.2174/15748871113089990045  0.84
2013 Moran JA, Rafii MS, Keller SM, Singh BK, Janicki MP. The National Task Group on Intellectual Disabilities and Dementia Practices consensus recommendations for the evaluation and management of dementia in adults with intellectual disabilities. Mayo Clinic Proceedings. 88: 831-40. PMID 23849993 DOI: 10.1016/j.mayocp.2013.04.024  0.84
2013 Desikan RS, Rafii MS, Brewer JB, Hess CP. An expanded role for neuroimaging in the evaluation of memory impairment. Ajnr. American Journal of Neuroradiology. 34: 2075-82. PMID 23764728 DOI: 10.3174/ajnr.A3644  0.84
2012 Ness S, Rafii M, Aisen P, Krams M, Silverman W, Manji H. Down's syndrome and Alzheimer's disease: Towards secondary prevention Nature Reviews Drug Discovery. 11: 655-656. PMID 22935789 DOI: 10.1038/nrd3822  0.84
2012 Rafii MS. Advances in the Treatment of Alzheimer's Disease Molecular and Cellular Therapeutics. 233-244. DOI: 10.1002/9781119967309.ch10  0.84
2011 Rafii MS, Walsh S, Little JT, Behan K, Reynolds B, Ward C, Jin S, Thomas R, Aisen PS. A phase II trial of huperzine A in mild to moderate Alzheimer disease. Neurology. 76: 1389-94. PMID 21502597 DOI: 10.1212/WNL.0b013e318216eb7b  0.84
2011 Rafii M, Taylor C, Coutinho A, Kim K, Galasko D. Comparison of the memory performance index with standard neuropsychological measures of cognition American Journal of Alzheimer's Disease and Other Dementias. 26: 235-239. PMID 21406427 DOI: 10.1177/1533317511402316  0.84
2010 Rafii MS, Brewer JB. Functional brain imaging in the clinical assessment of consciousness. Plos Biology. 8: e1000548. PMID 21151340 DOI: 10.1371/journal.pbio.1000548  0.84
2010 Rafii MS. The pulse of drug development for Alzheimer's disease. Reviews On Recent Clinical Trials. 5: 57-62. PMID 20205688 DOI: 10.2174/157488710790820490  0.84
2009 Kovacevic S, Rafii MS, Brewer JB. High-throughput, fully automated volumetry for prediction of MMSE and CDR decline in mild cognitive impairment. Alzheimer Disease and Associated Disorders. 23: 139-45. PMID 19474571 DOI: 10.1097/WAD.0b013e318192e745  0.84
2009 Rafii MS, Aisen PS. Recent developments in Alzheimer's disease therapeutics. Bmc Medicine. 7: 7. PMID 19228370 DOI: 10.1186/1741-7015-7-7  0.84
2008 Rafii MS, Galasko D. Primary care screening for dementia and mild cognitive impairment [1] Jama - Journal of the American Medical Association. 299: 1132. PMID 18334685  0.84
2007 Kuwabara H, Kumar A, Rafii M, Holt D, Dannals R, Resnick SM, Wong DF. Construction of binding potential maps of Pittsburgh Compound B by bolus-plus-infusion transformation (BPIT): Comparison to popular reference tissue approaches Journal of Cerebral Blood Flow and Metabolism. 27: PP09-07U.  0.84
2006 Rafii MS. Case 14: a woman with bilateral Bell's palsy. Medgenmed : Medscape General Medicine. 8: 23. PMID 17415306  0.84
2006 Rafii MS, Hillis AE. Compendium of cerebrovascular diseases. International Review of Psychiatry (Abingdon, England). 18: 395-407. PMID 17085359 DOI: 10.1080/09540260600935405  0.84
2006 Rafii MS, Hagiwara H, Mercado ML, Seo NS, Xu T, Dugan T, Owens RT, Hook M, McQuillan DJ, Young MF, Fallon JR. Biglycan binds to alpha- and gamma-sarcoglycan and regulates their expression during development. Journal of Cellular Physiology. 209: 439-47. PMID 16883602 DOI: 10.1002/jcp.20740  0.84
2006 Mercado ML, Amenta AR, Hagiwara H, Rafii MS, Lechner BE, Owens RT, McQuillan DJ, Froehner SC, Fallon JR. Biglycan regulates the expression and sarcolemmal localization of dystrobrevin, syntrophin, and nNOS. Faseb Journal : Official Publication of the Federation of American Societies For Experimental Biology. 20: 1724-6. PMID 16807372 DOI: 10.1096/fj.05-5124fje  0.84
2005 Rafii MS, Koenig M, Ziai WC. Orolingual angioedema associated with ACE inhibitor use after rtPA treatment of acute stroke. Neurology. 65: 1906. PMID 16380611 DOI: 10.1212/01.wnl.0000190262.59672.4c  0.84
2000 Berzin TM, Zipser BD, Rafii MS, Kuo-Leblanc V, Yancopoulos GD, Glass DJ, Fallon JR, Stopa EG. Agrin and microvascular damage in Alzheimer's disease. Neurobiology of Aging. 21: 349-55. PMID 10867220 DOI: 10.1016/S0197-4580(00)00121-4  0.84
2000 Shankle WR, Landing BH, Rafii MS, Hara J, Fallon JH, Romney AK, Boyd JP. Cyberchild: A database of the microscopic development of the postnatal human cerebral cortex from birth to 72 months Neurocomputing. 32: 1109-1114. DOI: 10.1016/S0925-2312(00)00285-X  0.84
1999 Donahue JE, Berzin TM, Rafii MS, Glass DJ, Yancopoulos GD, Fallon JR, Stopa EG. Agrin in Alzheimer's disease: altered solubility and abnormal distribution within microvasculature and brain parenchyma. Proceedings of the National Academy of Sciences of the United States of America. 96: 6468-72. PMID 10339611 DOI: 10.1073/pnas.96.11.6468  0.84
1999 Shankle WR, Rafii MS, Landing BH, Fallon JH. Approximate doubling of numbers of neurons in postnatal human cerebral cortex and in 35 specific cytoarchitectural areas from birth to 72 months. Pediatric and Developmental Pathology : the Official Journal of the Society For Pediatric Pathology and the Paediatric Pathology Society. 2: 244-59. PMID 10191348 DOI: 10.1007/s100249900120  0.84
1998 Shankle WR, Landing BH, Rafii MS, Schiano A, Chen JM, Hara J. Evidence for a postnatal doubling of neuron number in the developing human cerebral cortex between 15 months and 6 years. Journal of Theoretical Biology. 191: 115-40. PMID 9631564 DOI: 10.1006/jtbi.1997.0570  0.84
Show low-probability matches.